{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:15:46Z","timestamp":1791814546761,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.oret.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:23:19Z","timestamp":1786548199000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Faricimab for Polypoidal Choroidal Vasculopathy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-1762","authenticated-orcid":false,"given":"Won Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-8033","authenticated-orcid":false,"given":"Junyeop","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-2797","authenticated-orcid":false,"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-0945","authenticated-orcid":false,"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-6220","authenticated-orcid":false,"given":"Paisan","family":"Ruamviboonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Hock","family":"Chuan Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0362-7285","authenticated-orcid":false,"given":"Yasuo","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Nguyen","family":"Duc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-3373","authenticated-orcid":false,"given":"Philippe","family":"Margaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-6428","authenticated-orcid":false,"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.08.003_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.003_bib2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40942-025-00744-8","article-title":"Recognition and treatment of polypoidal choroidal vasculopathy and age-related macular degeneration in British Columbia","volume":"11","author":"Lee","year":"2025","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2026.08.003_bib3","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/diagnostics13101680","article-title":"New concepts for the diagnosis of polypoidal choroidal vasculopathy","volume":"13","author":"Zhao","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.oret.2026.08.003_bib4","article-title":"Polypoidal choroidal vasculopathy: a comprehensive clinical update","volume":"11","author":"Kumar","year":"2019","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib5","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3390\/jcm11164766","article-title":"European prevalence of polypoidal choroidal vasculopathy: a systematic review, meta-analysis, and forecasting study","volume":"11","author":"van Dijk","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.oret.2026.08.003_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","article-title":"Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians","volume":"101","author":"Yadav","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41433-020-0834-z","article-title":"Prevalence of polypoidal choroidal vasculopathy in Caucasian patients as estimated from optical coherence tomography signs","volume":"35","author":"Liew","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.08.003_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4274\/tjo.galenos.2021.16578","article-title":"Prevalence of polypoidal choroidal vasculopathy in eyes with neovascular age-related macular degeneration resistant to intravitreal anti-VEGF treatment","volume":"52","author":"Mente\u015f","year":"2022","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/11206721221100624","article-title":"Peripheral and macular polypoidal choroidal vasculopathy: a retrospective comparative case series","volume":"33","author":"Venkatesh","year":"2023","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00417-015-2933-2","article-title":"The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients","volume":"253","author":"Cheung","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK","volume":"106","author":"Ogura","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaophthalmol.2025.0250","article-title":"Aflibercept with vs without reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"143","author":"Chong","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamaophthalmol.2025.5098","article-title":"Aflibercept 8 mg in polypoidal choroidal vasculopathy: post hoc analysis of the PULSAR randomized clinical trial","volume":"144","author":"Lee","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib16","series-title":"Presented at the 24th European Society of Retina Specialists Congress; September 19\u201322, 2024; Barcelona, Spain","first-page":"19","article-title":"Aflibercept 8 mg monotherapy results in regression of polypoidal lesions that is maintained over 96 weeks in patients with PCV in the PULSAR phase 3 trial","author":"Silva","year":"2024"},{"key":"10.1016\/j.oret.2026.08.003_bib17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.survophthal.2024.12.006","article-title":"Enhancing anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy: a meta-analysis","volume":"70","author":"Lin","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ajo.2016.06.014","article-title":"Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy","volume":"169","author":"Cho","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/eye.2015.251","article-title":"Photodynamic therapy: current role in the treatment of chorioretinal conditions","volume":"30","author":"Newman","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.08.003_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/OPTH.S385827","article-title":"Polypoidal choroidal vasculopathy: an update on diagnosis and treatment","volume":"17","author":"Sen","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib21","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cells9081869","article-title":"Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab","volume":"9","author":"Khan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.oret.2026.08.003_bib22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.oret.2026.08.003_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.08.003_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.003_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","article-title":"Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial","volume":"67","author":"Mori","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib26","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials","volume":"261","author":"Takahashi","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2026.08.003_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15296","article-title":"Plastic roles of pericytes in the blood-retinal barrier","volume":"8","author":"Park","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.oret.2026.08.003_bib29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajo.2024.10.017","article-title":"Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for exudative age-related macular degeneration","volume":"270","author":"Kaufmann","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.003_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100142","article-title":"Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation","volume":"14","author":"Zou","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.oret.2026.08.003_bib31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.003_bib32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.08.003_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","article-title":"Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials","volume":"9","author":"Danzig","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.08.003_bib34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026003921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026003921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:51:56Z","timestamp":1790369516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026003921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"alternative-id":["S2468653026003921"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.08.003","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Faricimab for Polypoidal Choroidal Vasculopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}